Related Experiment Video
Updated: Sep 16, 2026

Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation
Published on: March 5, 2018
Activation of caspases in p53-induced transactivation-independent apoptosis
1Department of Molecular Cellular Oncology, Tokyo Medical and Dental University.
Abstract:
Though p53-induced apoptosis plays an important role in tumor suppression, the mechanism(s) by which p53 induces apoptosis is still unclear. To elucidate the p53-induced apoptotic pathway, we examined the role of p53 transactivation activity and caspase in J138V5C cells carrying a human temperature-sensitive (ts) p53 mutant (138Ala-->Val). The results showed that p53-induced apoptosis was not blocked by cycloheximide, which effectively prevented the expression of p53 target genes, indicating that transactivation was not essential for p53-induced apoptosis in this system. Western blot analysis showed that PARP, CPP32 and ICH-1 precursors were cleaved during apoptosis. The CPP32-preferential tetrapeptide inhibitor Ac-DEVD-CHO blocked the cleavage of ICH-1 and PARP precursors, suggesting that CPP32 or some other DEVD-sensitive caspase(s) is the upstream activator of ICH-1. We also examined the role of the Fas pathway by using Fas and Fas ligand-neutralizing antibodies. Both antibodies failed to block p53-induced apoptosis, suggesting that the Fas pathway was not essential for p53-induced apoptosis in this system. Taken together, our results indicate that p53-induced, transactivation-independent apoptosis in Jurkat cells involves sequential activation of CPP32 or some other DEVD-sensitive caspase(s) and ICH-1, via a Fas-independent pathway.
Insights
p53-induced apoptosis, crucial for tumor suppression, proceeds independently of gene activation. This pathway involves sequential activation of caspases like CPP32 and ICH-1, bypassing the Fas pathway.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- p53 is a critical tumor suppressor.
- The precise mechanisms of p53-induced apoptosis remain incompletely understood.
- Understanding these pathways is vital for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the role of p53 transactivation activity in apoptosis.
- To elucidate the specific caspase cascade involved in p53-mediated cell death.
- To determine the involvement of the Fas pathway in p53-induced apoptosis.
Main Methods:
- Utilized J138V5C cells with a temperature-sensitive p53 mutant.
- Assessed apoptosis induction with and without cycloheximide (inhibitor of gene expression).
- Employed Western blot analysis to detect protein cleavage (PARP, CPP32, ICH-1) and caspase inhibitors (Ac-DEVD-CHO).
- Investigated the Fas pathway using neutralizing antibodies against Fas and Fas ligand.
Main Results:
- p53-induced apoptosis occurred independently of p53 transactivation activity, as cycloheximide did not block it.
- Cleavage of Poly(ADP-ribose) polymerase (PARP), CPP32, and ICH-1 precursors was observed during apoptosis.
- A caspase inhibitor (Ac-DEVD-CHO) blocked the cleavage of ICH-1 and PARP, indicating CPP32 or a similar caspase is upstream of ICH-1.
- The Fas pathway was not essential for p53-induced apoptosis, as Fas-neutralizing antibodies had no inhibitory effect.
Conclusions:
- p53 induces apoptosis in Jurkat cells through a transactivation-independent mechanism.
- The pathway involves the sequential activation of CPP32 (or other DEVD-sensitive caspases) and ICH-1.
- This apoptotic cascade operates independently of the Fas signaling pathway.
Related Concept Videos
Abnormal Proliferation
Apoptosis
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

